SOD1 and amyotrophic lateral sclerosis: Thus, in our study, the rationale for starting the treatments at 14 weeks of age in SOD1-G93A mice resides in the belief that this time window of pharmacological intervention could strongly improve the translational impact of the results, providing the basis for possible future trials in ALS patients, and particularly those affected by a sporadic form of the disease, whose treatment cannot be initiated before the onset of symptoms.